MAS
UTHR icon

Meeder Advisory Services’s United Therapeutics UTHR Stock Holding History

Meeder Advisory Services’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Sell
638
-23
-3% -$13K 0.01% 512
2026
Q1 		$392K Buy
661
+26
+4% +$12.9K 0.02% 452
2025
Q4 		$310K Buy
635
+50
+9% +$23.3K 0.01% 515
2025
Q3 		$245K Buy
+585
New +$197K 0.01% 540
2025
Q1 		– Sell
-656
Closed -$231K – 594
2024
Q4 		$231K Buy
656
+28
+4% +$10.3K 0.01% 505
2024
Q3 		$225K Buy
+628
New +$212K 0.01% 500

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Meeder Advisory Services's UTHR Position: Q2 2026 in Review

Meeder Advisory Services reduced its United Therapeutics (UTHR) stake by 3.5% in Q2 2026, selling an estimated $13K and leaving 638 shares worth $346K. The position accounts for 0.01% of the portfolio, ranked #512.

Meeder Advisory Services first reported a position in UTHR in Q3 2024 and has held it in 6 quarters since. The position peaked at $392K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Meeder Advisory Services held 638 shares of United Therapeutics worth $346K as of Q2 2026.
  • Meeder Advisory Services sold 23 United Therapeutics shares in Q2 2026, an estimated $13K.
  • United Therapeutics made up 0.01% of Meeder Advisory Services's portfolio in Q2 2026, its #512 holding.
  • Meeder Advisory Services first reported a position in United Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Meeder Advisory Services's United Therapeutics position peaked at $392K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.